Vision Mission & Strength
R & D
Niprolac Oral Sol
Starcal D Forte
NIPRO JMI Pharma Ltd. (NJP) is contributing in developing a world-class practicein the pharma industry of Bangladesh by bridling the unment challenges in healthcare sector. It is one of the fastest growing pharmaceutical companies in Bangladesh, started its journey in 2012 with collaboration of NIPRO Corporation; a Japan based giant multinational company, a press release said.
NIPRO JMI Pharma Limited (NJP) has introduced Linagliptin (Lijenta) and Empagliflozin (Empa), which are the breakthroughs in diabetic management and aiding millions of diabetic patients in the country....
NIPRO JMI Pharma Ltd. has celebrated Bangla New Year - 1426 at Corporate office....
Japan Bangladesh joint venture company- NIPRO JMI Pharma held its annual sales conference 2018 at International Convention City, Bashundhara, Dhaka.....
Bisoprolol Hemifumarate is the most selective ÃŸ1 blocker. It displays highest level of
affinity for the ÃŸ1 receptor than any other beta-blocker available up to now. Selectively
blocks ÃŸ1 adrenergic receptor in the heart and vascular smooth muscle and reduces
heart rate and cardiac output resulting in decrease of arterial hypertension. Lipid
metabolism can be adversely affected by ÃŸ-blockers, in patients with non-ÃŸ1 selective
ÃŸ1-blocker, but Bisoprolol does not cause any change in the cholesterol fraction
including the cardioprotective HDL-cholesterol, in long-term therapy.